Open AccessEarly Clinical and Programmatic Outcomes with Tenofovir-Based Antiretroviral Therapy in Zambia
Author(s) -
H. Benjamin,
Albert Mwango,
Mark J. Giganti,
Lloyd Mulenga,
Bushimbwa Tambatamba-Chapula,
Stewart E. Reid,
Carolyn BoltonMoore,
Namwinga Chintu,
Priscilla Lumano Mulenga,
Elizabeth M. Stringer,
Robert Sheneberger,
Peter Mwaba,
Jeffrey S. A. Stringer
Publication year - 2010
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0b013e3181c6c65c
Subject(s) - hazard ratio , zidovudine , interquartile range , stavudine , tenofovir , medicine , confidence interval , proportional hazards model , human immunodeficiency virus (hiv) , immunology , viral disease
In July 2007, amid some controversy over cost, Zambia was the first African country to introduce tenofovir (TDF) as a component of first-line antiretroviral therapy (ART) on a wide scale.